Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.
Follow RVMD
Revolution Medicines, Inc. (RVMD) EV/Sales
As of 16 October 2026, Revolution Medicines, Inc. (RVMD) trades at a EV/Sales of 1,287×. Over the past ten years it has ranged from −1.3× (March 2020) to 1,625× (August 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 52.0× | 45.62% |
| FY2022 | 35.7× | (20.30%) |
| FY2021 | 44.8× | 9.30% |
| FY2020 | 41.0× | — |
| FY2019 | −0.9× | — |
| FY2018 | −0.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | 52.0× | (23.59%) |
| Jun 2023 | 68.0× | 96.92% |
| Mar 2023 | 34.5× | (3.22%) |
| Dec 2022 | 35.7× | (1.88%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| ARGX argenex SE compare | 8.9× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| RVMD Revolution Medicines, Inc. | 1,287× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)